Compare Natera Inc. Common Stock (NTRA) vs State Street Corporation Common Stock (STT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs State Street Corporation Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while State Street Corporation Common Stock trades at $167.94 (market cap $47.83B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and State Street Corporation Common Stock pays a 2.11% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and State Street Corporation Common Stock for 2 Days on average.
| NTRA | STT | |
|---|---|---|
Market Cap | $57.03B | $47.83B |
Volume | 1,131,157 | 2,907,463 |
Sector | Health | Financials |
52-Week High | $425.64 | $194.26 |
52-Week Low | $179.42 | $111.37 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $56.18B | $74.34B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
State Street (STT) trades at $173.99, down 0.54% with bearish technical signals despite strong Q3 2026 earnings beat. The stock faces headwinds from a revenue miss and ongoing investigation, though fundamentals show robust profitability with 22.95% net margin and consistent earnings growth. Analyst consensus remains positive with $183.55 price target, but technical indicators show selling pressure with support at $172.
Outlook is mixed with strong fundamentals supporting long-term value, but near-term risks from the securities investigation and bearish technicals create uncertainty. The 13% revenue growth and record AUM provide upside potential, though investors should monitor legal developments and expense trends that could impact sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About State Street Corporation Common Stock
State Street provides investment servicing, custody, and asset management services to institutional investors. Its asset management business includes the SPDR ETF range.
Read more on STT →
